General practitioner and nurse experiences of type 2 diabetes management and prescribing in primary care: a qualitative review following the introduction of funded SGLT2i/GLP1RA medications in Aotearoa New Zealand.
初級醫療中全科醫生和護理人員對第二型糖尿病管理和處方的經驗:在新西蘭 Aotearoa 引入資助的 SGLT2i/GLP1RA 藥物後的質性回顧。
Prim Health Care Res Dev 2024-09-16
The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
第二型糖尿病患者中鈉葡萄糖共同轉運蛋白2抑製劑和葡萄糖樣肽-1受體激動劑的處方模式:一項兩個中心的回顧性橫斷面研究。
Front Public Health 2023-01-27
Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study.
影響香港已患心血管疾病/慢性腎臟病型2糖尿病患者處方鈉葡萄糖共同轉運蛋白2抑製劑的因素:一項質性研究。
BMC Prim Care 2022-12-20
Empagliflozin and dulaglutide: community awareness project promotes improved access to newly funded medications for Pacific patients with type 2 diabetes.
Empagliflozin和dulaglutide:社區意識計畫促進太平洋地區2型糖尿病患者獲得新資助藥物的便利。
N Z Med J 2023-03-27
'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation.
心臟病專家和腎臟病專家對於鈉葡萄糖共轉運輸蛋白2抑制劑開始治療的看法:一項探索性研究。
Intern Med J 2024-04-22
A diabetes registrar assisted workflow intervention in general practice for systematic initiation of cardiorenal medications for patients with type 2 diabetes and albuminuria in Aotearoa New Zealand.
一項針對新西蘭Aotearoa地區2型糖尿病患者的心腎藥物系統性開始的一項糖尿病註冊醫師輔助工作流介入。
N Z Med J 2023-12-16
Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors.
中國醫生對於胰高血糖素樣肽-1受體激動劑和鈉-葡萄糖共轉運蛋白2抑制劑的知識差距及處方模式。
Sci Rep 2024-08-07
Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
2型糖尿病中患者重要的結果:鈉-葡萄糖共轉運蛋白-2抑制劑和胰高血糖素樣肽-1受體激動劑的範例。
Diab Vasc Dis Res 2024-08-14
GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease.
GLP-1 受體激動劑和 SGLT2 抑制劑降低血糖並減少心血管疾病及糖尿病腎病的風險。
J Am Board Fam Med 2024-08-14
Qualitative Evaluation to Understand Barriers and Facilitators to Prescribing Angiotensin Receptor-Neprilysin Inhibitors (ARNi) and Sodium-Glucose Cotransporter Inhibitors (SGLT2i) in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).
質性評估以了解在射血分數降低的心臟衰竭(HFrEF)患者中開立血管緊張素受體-中性酯酶抑制劑(ARNi)和鈉-葡萄糖共轉運蛋白抑制劑(SGLT2i)的障礙與促進因素。
J Am Pharm Assoc (2003) 2024-08-29